Comparison of endothelial barrier functional recovery after implantation of a novel biodegradable polymer sirolimus-eluting stent in comparison to durable and biodegradable polymer everolimus-eluting stents.
暂无分享,去创建一个
R. Virmani | A. Finn | F. Kolodgie | Qi Cheng | A. Cornelissen | Liang Guo | S. Torii | M. Srivastava | H. Jinnouchi | A. Sakamoto | Raquel Fernandez | K. Paek | Salome H Kuntz | Kathryn M. Harris | Kathryn Harris
[1] R. Virmani,et al. Direct Targeting of the mTOR (Mammalian Target of Rapamycin) Kinase Improves Endothelial Permeability in Drug-Eluting Stents—Brief Report , 2018, Arteriosclerosis, thrombosis, and vascular biology.
[2] V. Ribeiro,et al. Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[3] N. Leeper,et al. Thrombotic Regulation From the Endothelial Cell Perspectives. , 2018, Arteriosclerosis, thrombosis, and vascular biology.
[4] V. Ribeiro,et al. First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[5] J. W. Louwerenburg,et al. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial. , 2018, JACC: Cardiovascular Interventions.
[6] R. Virmani,et al. Endothelial Barrier Protein Expression in Biodegradable Polymer Sirolimus-Eluting Versus Durable Polymer Everolimus-Eluting Metallic Stents. , 2017, JACC. Cardiovascular interventions.
[7] K. Bønaa,et al. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. , 2016, The New England journal of medicine.
[8] J. Mehilli,et al. Stent Polymers: Do They Make a Difference? , 2016, Circulation. Cardiovascular interventions.
[9] Erik Jørgensen,et al. Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography , 2016, Circulation.
[10] K. Dawkins,et al. The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer safety study , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[11] Ning Wang,et al. Local VE-cadherin mechanotransduction triggers long-ranged remodeling of endothelial monolayers , 2015, Journal of Cell Science.
[12] Michel Vert,et al. Head-to-Head Comparison of a Drug-Free Early Programmed Dismantling Polylactic Acid Bioresorbable Scaffold and a Metallic Stent in the Porcine Coronary Artery: Six-Month Angiography and Optical Coherence Tomographic Follow-Up Study , 2014, Circulation. Cardiovascular interventions.
[13] A. Finn,et al. Sirolimus-FKBP12.6 Impairs Endothelial Barrier Function Through Protein Kinase C-&agr; Activation and Disruption of the p120–Vascular Endothelial Cadherin Interaction , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[14] R. Virmani,et al. Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. , 2013, The Journal of invasive cardiology.
[15] A. Kirtane,et al. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. , 2013, JACC. Cardiovascular interventions.
[16] A. Tzafriri,et al. Mechanisms of Tissue Uptake and Retention in Zotarolimus-Coated Balloon Therapy , 2013, Circulation.
[17] E. Dejana,et al. The role of VE-cadherin in vascular morphogenesis and permeability control. , 2013, Progress in molecular biology and translational science.
[18] H. Bøtker,et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial , 2010, The Lancet.
[19] Renu Virmani,et al. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. , 2009, JACC. Cardiovascular imaging.
[20] F. Orsenigo,et al. The role of adherens junctions and VE-cadherin in the control of vascular permeability , 2008, Journal of Cell Science.
[21] G. Davı̀,et al. Platelet activation and atherothrombosis. , 2007, The New England journal of medicine.
[22] F. Luscinskas,et al. Endothelial-Dependent Mechanisms of Leukocyte Recruitment to the Vascular Wall , 2007, Circulation research.
[23] P. Fitzgerald,et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. , 2006, Journal of the American College of Cardiology.
[24] David A. Schultz,et al. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress , 2005, Nature.
[25] Shu Chien,et al. Activation of integrins in endothelial cells by fluid shear stress mediates Rho‐dependent cytoskeletal alignment , 2001, The EMBO journal.
[26] W. J. van der Giessen,et al. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. , 1998, Journal of the American College of Cardiology.